Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx

NCT00002702 is registered in ClinicalTrials.gov with European Institute of Oncology as lead sponsor.

NCT NCT00002702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx
Lead sponsor
European Institute of Oncology
Phase
Phase 3
Overall status
Unknown status
Start date
September 30, 1992
Completion date
Not reported
Enrollment
260 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer